ALTERNATIVE FINANCING FORMS
FOR ENTREPRENEURS AND INVESTORS
3 questions to smart minds
Photo: Lutz Voelker

The life science sector is in upheaval

In addition 3 questions to Lutz Voelker

Photo: Lutz Voelker
More Inter­views
Photo: Michael Sinhart
11. March 2026
Michael Sinhart
Private invest­ments in infra­struc­ture — current topics and trends
Photo: Marko Maschek
11. Febru­ary 2026
Marko Maschek
Influence of the secu­rity and defense indus­try (SVI) on the German economy — Can private capi­tal contri­bute to deterrence?
Photo: Carl-Jan von der Goltz
25. Febru­ary 2026
Carl-Jan von der Goltz
How the 2026 turn­around can succeed in terms of financing
Show all
5. Septem­ber 2017

The life science sector has always been a step­child of the German finan­cing indus­try. One exam­ple: “Immu­nic Thera­peu­tics” from Martins­ried near Munich has closed a Series A finan­cing round with a total volume of EUR 31.7 million. The inves­tors all come from abroad: Omega Funds (Boston, MA, USA) and Fund+ (Leuven, Belgium) have joined the exis­ting inter­na­tio­nal inves­tor consor­tium, led by Dutch VC inves­tor LSP, with the invest­ment tota­ling EUR 10 million. Why is that? And where do life science compa­nies thrive best?

1.
2.
3.

Subscribe newsletter

Here you can read about the latest transactions, IPOs, private equity deals and venture capital investments, who has raised a new fund, how Buy & Build activities are going.

Get in touch

Contact us!
fyb [at] fyb.de

Send email